Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date

B cells in general and BAFF (B cell activating factor of the tumor necrosis factor [TNF] family) in particular have been primary targets of recent clinical trials in systemic lupus erythematosus (SLE). In 2011, belimumab, a monoclonal antibody against BAFF, became the first biologic agent approved f...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenert, Aleksander, Niewold, Timothy B, Lenert, Petar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357079/
https://www.ncbi.nlm.nih.gov/pubmed/28331294
http://dx.doi.org/10.2147/DDDT.S114552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357079/
https://www.ncbi.nlm.nih.gov/pubmed/28331294
http://dx.doi.org/10.2147/DDDT.S114552

Ejemplares similares